MAIA director buys 37,595 shares at $1.32

MAIA Biotechnology director Ramiro Guerrero increased his direct ownership with a September 2026 open-market share purchase.

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. (MAIA) director Ramiro Guerrero purchased additional Common Stock in an open-market or private transaction on September 10, 2026. He bought 37,595 shares at a reported price of $1.3171 per share, bringing his directly held stake to 773,296 shares after the transaction.

Insider Trade Summary

Net Buyer: 37,595 shares

Net Buy 1 txn

Insider Guerrero Ramiro

Role Director

Bought 37,595 shs ($50K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	37,595	$1.3171	$50K

Holdings After Transaction: Common Stock — 773,296 shares (Direct)

Key Figures

Shares purchased: 37,595 shares Purchase price per share: $1.3171 per share Shares owned after transaction: 773,296 shares

3 metrics

Shares purchased 37,595 shares Common Stock acquired by director on September 10, 2026

Purchase price per share $1.3171 per share Price reported for the September 10, 2026 purchase

Shares owned after transaction 773,296 shares Director’s direct MAIA Common Stock holdings following the transaction

Key Terms

Purchase in open market or private transaction, Common Stock, direct ownership

3 terms

Purchase in open market or private transaction financial

"transaction described as Purchase in open market or private transaction"

Common Stock financial

"security title reported as Common Stock for the transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

direct ownership financial

"ownership type for the shares is reported as direct"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MAIA director Ramiro Guerrero report on this Form 4 for MAIA?

He reported a purchase of 37,595 shares of MAIA Common Stock on September 10, 2026 in an open-market or private transaction, increasing his direct holdings.

At what price did the MAIA director buy shares according to this Form 4?

The filing reports a purchase price of $1.3171 per share for the 37,595 MAIA Common Stock shares acquired on September 10, 2026.

How many MAIA shares does Ramiro Guerrero own after this reported transaction?

After the September 10, 2026 purchase, Ramiro Guerrero directly owns 773,296 shares of MAIA Biotechnology, Inc. Common Stock, as stated in the filing.

Was the MAIA insider trade made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not checked, meaning the reported purchase was not affirmed as being made under a Rule 10b5-1 trading plan.

Is the MAIA insider transaction a purchase or a sale?

The Form 4 reports a purchase of MAIA Common Stock by director Ramiro Guerrero, coded as a “Purchase in open market or private transaction.” No sales are reported in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 09:04 AM Accepted by SEC EDGAR 09/14/2026 - 09:03 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guerrero Ramiro

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		P		37,595	A	$1.3171	773,296	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Ramiro Guerrero	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)